Recombinant Human BACE1, C13&N15-labeled

• Cat.No.: BACE1-219H
• Product Overview: Recombinant Human BACE1 MS Standard Protein, C13 and N15-labeled (BACE1, Heavy Labeled) Thr 22 - Thr 457 (Accession # NP_036236.1) was produced in human 293 cells (HEK293).

Specification

• Description: Beta-secretase 1 (BACE1) also known as beta-site APP cleaving enzyme 1 (beta-site amyloid precursor protein cleaving enzyme 1), memapsin-2 (membrane-associated aspartic protease 2), and aspartyl protease 2 (ASP2), β-Secretase , and is a member of the peptidase A1 protein family, BACE1 is a type I integral membrane glycoprotein and aspartic protease that is found mainly in the Golgi. BACE1 is an aspartic-acid protease important in the pathogenesis of Alzheimer"s disease, and in the formation of myelin sheaths in peripheral nerve cells.[1] The transmembrane protein contains two active site aspartate residues in its extracellular protein domain and may function as a dimer. This protease is responsible for the proteolytic processing of the amyloid precursor protein (APP). Generation of the 40 or 42 amino acid-long amyloid-β peptides that aggregate in the brain of Alzheimer"s patients requires two sequential cleavages of the APP. Extracellular cleavage of APP by BACE creates a soluble extracellular fragment and a cell membrane-bound fragment referred to as C99. The elevation of BACE1 levels can be induced by amyloid plaques surrounding neurons at early stages of pathology before neuron death occurs, and may drive a positive-feedback loop in AD. [2-3]
• Source: HEK293
• Species: Human
• Form: Lyophilized from 0.22 μm filtered solution in PBS, pH7.4. Normally Mannitol or Trehalose are added as protectants before lyophilization.
• Molecular Mass: BACE1, Heavy Labeled, fused with 6×His tag at the C-terminus, has a calculated MW of 49.2 kDa. The predicted N-terminus is Thr 22. DTT-reduced Protein migrates as 50-65 kDa due to glycosylation.
• Endotoxin: Less than 1.0 EU per μg of the BACE1, Heavy Labeled by the LAL method.
• Purity: >95% as determined by SDS-PAGE.
• Storage: Avoid repeated freeze-thaw cycles.No activity loss was observed after storage at:In lyophilized state for 1 year (4oC-8oC); After reconstitution under sterile conditions for 1 month (4oC-8oC) or 3 months (-20oC to -70oC).

Gene Information

• Gene Name: BACE1 beta-site APP-cleaving enzyme 1 [ Homo sapiens ]
• Official Symbol: BACE1
• Synonyms: BACE1; beta-site APP-cleaving enzyme 1; BACE, beta site APP cleaving enzyme; beta-secretase 1; asp 2; memapsin-2; APP beta-secretase; aspartyl protease 2; beta-site APP cleaving enzyme 1; beta-secretase 1 precursor variant 1; transmembrane aspartic proteinase Asp2; membrane-associated aspartic protease 2; beta-site amyloid beta A4 precursor protein-cleaving enzyme; ASP2; BACE; HSPC104; FLJ90568; KIAA1149
• Gene ID: 23621
• mRNA Refseq: NM_001207048
• Protein Refseq: NP_001193977
• MIM: 604252
• UniProt ID: P56817
• Chromosome Location: 11q23-q24
• Pathway: Alzheimers disease, organism-specific biosystem; Alzheimers disease, conserved biosystem
• Function: aspartic-type endopeptidase activity; beta-aspartyl-peptidase activity; enzyme binding; peptidase activity

Reviews

07/27/2020

Such support ensures researchers have access to reliable tools and expertise, facilitating their investigations into the functions, mechanisms, and disease relevance of BACE1 protein.

12/23/2019

A manufacturer can serve as a collaborative partner, engaging in discussions, and exchanging knowledge with researchers.

09/30/2019

Using BACE1 protein in trials provides advantages such as its involvement in cellular processes and its disease associations.

Q&As

Are there any potential side effects associated with BACE1 inhibition?

Yes, several clinical trials are underway to assess the safety and efficacy of BACE1 inhibitors in treating Alzheimer's disease.

How is BACE1 linked to Alzheimer's disease?

BACE1 is implicated in Alzheimer's disease as it initiates the cleavage of APP, leading to the formation of beta-amyloid plaques, a hallmark of the disease.

How can BACE1 inhibitors potentially benefit Alzheimer's patients?

BACE1 inhibitors may slow down or prevent the accumulation of beta-amyloid plaques, potentially delaying the progression of Alzheimer's disease.

Are there any ongoing clinical trials involving BACE1 inhibitors?

Yes, several clinical trials are underway to assess the safety and efficacy of BACE1 inhibitors in treating Alzheimer's disease.

Are there clinical applications of BACE1 inhibitors?

Yes, BACE1 inhibitors are being explored as potential therapeutic agents for Alzheimer's disease to reduce the production of beta-amyloid peptides.